
Package Leaflets
Hepa-Merz® Granules 3000
Hepa-Merz® Infusion Concentrate
Dosage Leaflet
Optimal use of Hepa Merz in HE
Hepa-Merz® Granules 3000
Hepa-Merz® Infusion Concentrate
Optimal use of Hepa Merz in HE
Obligatory texts Hepa-Merz®
EU:
Hepa- Merz® Granules
Active substance: L-ornithine- L-aspartate
Indications: Treatment of concomitant disease and sequelae due to impaired detoxification activity (e.g. in cirrhosis of the liver) with the symptoms of latent and manifest hepatic encephalopathy. Contains orange yellow S (E110), fructose,
For risks and side effects please read package insert and ask your doctor or pharmacist.
Version July 2019
Merz Pharmaceuticals GmbH, 60048 Frankfurt
LATAM:
Hepa- Merz® Granules
Active substance: L-ornithine- L-aspartate
Indications: Treatment of concomitant disease and sequelae due to impaired detoxification activity (e.g. in cirrhosis of the liver) with the symptoms of latent and manifest hepatic encephalopathy. Contains orange yellow S (E110), fructose, aspartame.
For risks and side effects please read package insert and ask your doctor or pharmacist.
Version July 2019
Merz Pharmaceuticals GmbH, 60048 Frankfurt